Lipid drug delivery: Sancilio Pharmaceuticals files for an $86 million IPO
Sancilio Pharmaceuticals Company, which markets, licenses and develops products based on its lipid drug delivery technology, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Riviera Beach, FL-based company, which was founded in 2006 and booked $22 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol SPCI. Sancilio Pharmaceuticals initially filed confidentially on May 14, 2015. UBS Investment Bank, Piper Jaffray, JMP Securities and FBR Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.